InTouch Indexed in Medline and Index Medicus

Publication
Article
OncologyONCOLOGY Vol 16 No 6
Volume 16
Issue 6

InTouch magazine, a sister publication of ONCOLOGY and Oncology News International, has been selected by the National Library of Medicine to be indexed and included in Index Medicus and Medline. InTouch is published by PRR for cancer patients and their families.

InTouch magazine, a sister publicationof ONCOLOGY and Oncology News International, has been selected by the NationalLibrary of Medicine to be indexed and included in Index Medicus and Medline. InTouch is published by PRR for cancer patients and their families.

"It’s a real tribute to the editorial quality of InTouch," said Steven T. Rosen, MD. Dr. Rosen, director of the Robert H.Lurie Comprehensive Cancer Center, serves as medical editor-in-chief for InTouch,which just celebrated its third year of publication.

The National Library of Medicine looks to an advisorycommittee—the Literature Selection Technical Review Committee—to choosejournals and other publications for citation. Composed of authoritiesknowledgeable in the field of biomedicine, the committee includes physicians,researchers, educators, editors, health science librarians, and historians whoreview and recommend titles for indexing. The databases in the Medlars system inwhich InTouch will appear are Index Medicus and Medline. These databases areavailable online internationally.

"We’re delighted that the NLM has recognized the integrity and valueof the information in InTouch," said Dr. Rosen. "Their endorsementfurthers our mission, which is to give patients and their loved ones the mostauthoritative and up-to-date information on cancer prevention and treatment sothat they can be better informed about their health care."

Recent Videos
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
Lisa J. States, MD, discussed further steps for improving early detection and screening methods in patients with Li–Fraumeni syndrome.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
9 Experts are featured in this series.
9 Experts are featured in this series.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
4 KOLs are featured in this series.
Related Content